FOXP3 and prostate cancer: For instance, in a murine renal cell carcinoma model and in castration-resistant prostate cancer, Pili et al. [18] showed that entinostat, in combination with either IL-2, survivin-based vaccine therapy, or immune checkpoint inhibition, reduced Foxp3 levels in Tregs, and this was associated with enhanced tumor growth inhibition.